MORGAN STANLEY PLC/CALL/ASTRAZENECA ADR/60/0.1/20.12.24 | Market Closed - Börse Stuttgart 19:59:31 27/06/2024 BST | ||
| 1.88 EUR | -5.53% |
|
| Current month | +8.15% | ||
| 1 month | +3.11% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 27/06/24 | 1.88 | -5.53% |
| 26/06/24 | 1.99 | -1.00% |
| 25/06/24 | 2.01 | +1.52% |
| 24/06/24 | 1.98 | +1.02% |
| 21/06/24 | 1.96 | +3.16% |
Delayed Quote Börse Stuttgart
Last update June 27, 2024 at 07:59 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | Morgan Stanley |
| WKN | MB3F1X |
| ISIN | DE000MB3F1X9 |
| Date issued | 08/02/2023 |
| Strike | 60 $ |
| Maturity | 20/12/2024 (176 Days) |
| Parity | 10 : 1 |
| Emission price | 1.3 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.1 € |
|---|---|
| Lowest since issue | 0.57 € |
| Spread | 0.01 € |
| Spread % | 0.53% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
155.9
USD
Average target price
174.4
USD
Spread / Average Target
+11.88%
- Stock Market
- Warrants
- Warrant
